Ulcerative colitis (UC) is a chronic inflammatory bowel disease that has a severe impact on patient physical and psychosocial health and quality of life. Because it is a progressive disease, early and effective treatment is important to control gastrointestinal inflammation and prevent long-term damage to the GI tract. While TNF inhibitors have been the mainstay of treatment for many years, more recently several novel targeted therapies have been approved for moderate-to-severe UC. These agents target the underlying mechanisms of UC pathogenesis and result in long-term clinical remission and improvement of UC symptoms for many patients.
This activity, Ulcerative Colitis: The Role of Targeted Therapy, will provide gastroenterologists with information on the immunopathology of UC, the efficacy and safety of more recently approved targeted therapies, and the latest guidelines for management of patients with UC.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Diabetes and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.